Results 111 to 120 of about 9,765 (234)
Вопросы вирусологииIntroduction. Altai Krai is a region with an unfavorable situation of HIV-1 and HCV infection, as well as HIV-1 and HCV coinfection. Due to this, it is necessary to study the HCV genetic variants and their drug resistance (DR) to direct-acting antivirals
Ilya A. Lapovok +8 more
doaj +1 more source
Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection
Annals of Hepatology, 2018 Background and aim. Grazoprevir is an NS3/4A protease inhibitor (PI), while elbasvir is an NS5A inhibitor. We performed this meta-analysis to directly compare grazoprevir plus elbasvir and ribavirin regimen vs.
Hussien Ahmed +6 more
doaj +1 more source
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry. [PDF]
J Gastroenterol Hepatol, 2022 Wong YJ +9 more
europepmc +1 more source
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation [PDF]
, 2012 A recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) can lead to accelerated allograft injury and fibrosis. The aim of this article is to report the first ever use of daclatasvir (DCV; also known as BMS‐790052), a potent orally ...
Alcaide +41 more
core +1 more source
Daclatasvir: potential role in hepatitis C
Drug Design, Development and Therapy, 2013 Choongho Lee College of Pharmacy, Dongguk University-Seoul, Goyang, Republic of Korea Abstract: Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma.
Lee C
doaj
Viruses, 2015 Sustained virological response (SVR) rates have increased dramatically following the approval of direct acting antiviral (DAA) therapies. While individual DAAs have a low barrier to resistance, most patients can be successfully treated using DAA ...
Kazuaki Chayama, C. Nelson Hayes
doaj +1 more source
Противовирусные лекарственные средства для лечения гепатита C [PDF]
, 2019 ГЕПАТИТ C /ЛЕК ТЕРПАРЕНТЕРАЛЬНО-ПЕРЕДАВАЕМЫЙ ГЕПАТИТ НИ-A, НИ-B /ЛЕК ТЕРПРОТИВОВИРУСНЫЕ СРЕДСТВА /ХИМЛЕКАРСТВ ХИМИЧЕСКАЯ СТАБИЛЬНОСТЬИНГИБИТОРЫ ПРОТЕАЗЫ NS3/NS4АИНГИБИТОРЫ БЕЛКА NS5AИНГИБИТОРЫ NS5B ПОЛИМЕРАЗЫДан обзор химической структуры и её связи с ...
Жерносек, А. К. +1 more
core
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. [PDF]
, 2006 Cell entry of hepatitis C virus, pseudoparticles (HCVpp) and cell culture grown virus (HCVcc), requires the interaction of viral glycoproteins with CD81 and other as yet unknown cellular factors.
Boullier, Agnès +6 more
core +1 more source
Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done
Annals of Hepatology, 2019 Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge.
Susana Llerena +7 more
doaj +1 more source
International Journal of Women's Health, 2019 Christophe Hézode,1 Paul Kwo,2 Jan Sperl,3 Peggy Hwang,4 Jianmin Long,4 Rohit Talwani,4 Michael N Robertson,4 Barbara A Haber4 1Service d’Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Cr ...
Hézode C +7 more
doaj